|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lynch TJ, Bell DW, Sordella R, et al:
Activating mutations in the epidermal growth factor receptor
underlying responsiveness of non-small-cell lung cancer to
gefitinib. N Engl J Med. 350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Paez JG, Jänne PA, Lee JC, et al: EGFR
mutations in lung cancer: correlation with clinical response to
gefitinib therapy. Science. 304:1497–1500. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pao W, Miller V, Zakowski M, et al: EGF
receptor gene mutations are common in lung cancers from
‘neversmokers’ and are associated with sensitivity of tumors to
gefitinib and erlotinib. Proc Natl Acad Sci USA. 101:13306–13311.
2004. View Article : Google Scholar
|
|
5
|
Kobayashi S, Boggon TJ, Dayaram T, et al:
EGFR mutation and resistance of non-small cell lung cancer to
gefitinib. N Engl J Med. 352:786–792. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pao W, Miller VA, Politi KA, et al:
Acquired resistance of lung adenocarcinomas to gefitinib or
erlotinib is associated with a second mutation in the EGFR kinase
domain. PLoS Med. 2:e732005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ohashi K, Sequist LV, Arcila ME, et al:
Lung cancers with acquired resistance to EGFR inhibitors
occasionally harbor BRAF gene mutations but lack mutations in KRAS,
NRAS, or MEK1. Proc Natl Acad Sci USA. 109:E2127–E2133. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ercan D, Xu C, Yanagita M, et al:
Reactivation of ERK signaling causes resistance to EGFR kinase
inhibitors. Cancer Discov. 2:934–947. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Faber AC, Corcoran RB, Ebi H, et al: BIM
expression in treatment-naïve cancers predicts responsiveness to
kinase inhibitors. Cancer Discov. 1:352–365. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Engelman JA, Zejnullahu K, Mitsudomi T, et
al: MET amplification leads to gefitinib resistance in lung cancer
by activating ERBB3 signaling. Science. 316:1039–1043. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bean J, Brennan C, Shih JY, et al: MET
amplification occurs with or without T790M mutations in EGFR mutant
lung tumors with acquired resistance to gefitinib or erlotinib.
Proc Natl Acad Sci USA. 104:20932–20937. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yauch RL, Januario T, Eberhard DA, et al:
Epithelial versus mesenchymal phenotype determines in vitro
sensitivity and predicts clinical activity of erlotinib in lung
cancer patients. Clin Cancer Res. 11:8686–8698. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Suda K, Tomizawa K, Fujii M, et al:
Epithelial to mesenchymal transition in an epidermal growth factor
receptor-mutant lung cancer cell line with acquired resistance to
erlotinib. J Thorac Oncol. 6:1152–1161. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mok TS, Wu YL, Thongprasert S, et al:
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N
Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mitsudomi T, Morita S, Yatabe Y, et al:
Gefitinib versus cisplatin plus docetaxel in patients with
non-small-cell lung cancer harboring mutations of the epidermal
growth factor receptor (WJTOG3405): an open label, randomized phase
3 trial. Lancet Oncol. 11:121–128. 2010. View Article : Google Scholar
|
|
16
|
Rosell R, Moran T, Queralt C, et al:
Screening for epidermal growth factor receptor mutations in lung
cancer. N Engl J Med. 361:958–967. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yun CH, Mengwasser KE, Toms AV, et al: The
T790M mutation in EGFR kinase causes drug resistance by increasing
the affinity for ATP. Proc Natl Acad Sci USA. 105:2070–2075. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Costa DB, Kobayashi S, Tenen DG and
Huberman MS: Pooled analysis of the prospective trials of gefitinib
monotherapy for EGFR-mutant non-small cell lung cancers. Lung
Cancer. 58:95–103. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nguyen KS, Kobayashi S and Costa DB:
Acquired resistance to epidermal growth factor receptor tyrosine
kinase inhibitors in non-small-cell lung cancers dependent on the
epidermal growth factor receptor pathway. Clin Lung Cancer.
10:281–289. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sequist LV, Bell DW, Lynch TJ and Haber
DA: Molecular predictors of response to epidermal growth factor
receptor antagonists in non-small-cell lung cancer. J Clin Oncol.
25:587–595. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Inukai M, Toyooka S, Ito S, et al:
Presence of epidermal growth factor receptor gene T790M mutation as
a minor clone in non-small cell lung cancer. Cancer Res.
66:7854–7858. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sequist LV, Martins RG, Spigel D, et al:
First-line gefitinib in patients with advanced non-small-cell lung
cancer harboring somatic EGFR mutations. J Clin Oncol.
26:2442–2449. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Toyooka S, Kiura K and Mitsudomi T: EGFR
mutation and response of lung cancer to gefitinib. N Engl J Med.
352:21362005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bell DW, Gore I, Okimoto RA, et al:
Inherited susceptibility to lung cancer may be associated with the
T790M drug resistance mutation in EGFR. Nat Genet. 37:1315–1316.
2005. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Koizumi F, Shimoyama T, Taguchi F, Saijo N
and Nishio K: Establishment of a human non-small cell lung cancer
cell line resistant to gefitinib. Int J Cance. 116:36–44. 2005.
View Article : Google Scholar
|
|
26
|
Engelman JA, Mukohara T, Zejnullahu K, et
al: Allelic dilution obscures detection of a biologically
significant resistance mutation in EGFR-amplified lung cancer. J
Clin Invest. 116:2695–2706. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Engelman JA, Zejnullahu K, Mitsudomi T, et
al: MET amplification leads to gefitinib resistance in lung cancer
by activating ERBB3 signaling. Science. 316:1039–1043. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Adjei AA: K-ras as a target for lung
cancer therapy. J Thorac Oncol. 3:S160–S163. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Suda K, Tomizawa K, Fujii M, et al:
Epithelial to mesenchymal transition in an epidermal growth factor
receptor-mutant lung cancer cell line with acquired resistance to
erlotinib. J Thorac Oncol. 6:1152–1161. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Rho JK, Choi YJ, Lee JK, et al: Epithelial
to mesenchymal transition derived from repeated exposure to
gefitinib determines the sensitivity to EGFR inhibitors in A549, a
non-small cell lung cancer cell line. Lung Cancer. 63:219–226.
2009. View Article : Google Scholar
|
